RXRX

Recursion Pharmaceuticals Inc

Oct 15 • 04:00PM ET

6.79

+0.90 15.28 %

Healthcare • Biotechnology • USA • NASD

Peers: ABCL SDGR DNLI NBIX CRSP BEAM NTLA EDIT VRTX RGNX

| Held by: ARKK ARKG XBI VTI IWM VB VBK IWO VXF SCHA

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	23.39%	Shs Outstand	425.48M	Perf Week	11.49%
Market Cap	2.95B	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-1.03%	Shs Float	332.98M	Perf Month	40.29%
Enterprise Value	2.51B	PEG	-	EPS next Q	-0.38	Inst Own	53.76%	Short Float	40.06%	Perf Quarter	23.01%
Income	-649.13M	P/S	45.69	EPS this Y	6.07%	Inst Trans	-0.73%	Short Ratio	4.45	Perf Half Y	20.39%
Sales	64.60M	P/B	3.20	EPS next Y	19.45%	ROA	-62.47%	Short Interest	133.41M	Perf YTD	0.44%
Book/sh	2.12	P/C	5.59	EPS next 5Y	18.35%	ROE	-86.34%	52W High	12.36 -45.06%	Perf Year	2.57%
Cash/sh	1.22	P/FCF	-	EPS past 3/5Y	-15.58% -35.28%	ROIC	-65.79%	52W Low	3.79 79.16%	Perf 3Y	-37.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	79.47% 90.93%	Gross Margin	-57.68%	Volatility	12.64% 8.53%	Perf 5Y	-
Dividend TTM	-	EV/Sales	38.87	EPS Y/Y TTM	-10.08%	Oper. Margin	-1005.82%	ATR (14)	0.48	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.58	Sales Y/Y TTM	30.14%	Profit Margin	-1004.91%	RSI (14)	69.61	Recom	2.43
Dividend Gr. 3/5Y	- -	Current Ratio	3.58	EPS Q/Q	-2.28%	SMA20	28.05%	Beta	0.88	Target Price	6.47
Payout	-	Debt/Eq	0.10	Sales Q/Q	33.34%	SMA50	32.82%	Rel Volume	5.98	Prev Close	5.89
Employees	-	LT Debt/Eq	0.07	Earnings	Aug 05 BMO	SMA200	16.93%	Avg Volume	29.99M	Price	6.79
IPO	Apr 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.05% 24.31%	Trades		Volume	179,197,188	Change	15.28%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$5
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Oct-13-25 12:12PM	2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (MarketBeat)
Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 05:00AM	Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference (Insider Monkey)
Oct-08-25 11:22AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) +16.44%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
05:50PM	Loading…
Oct-07-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.42%
Oct-03-25 09:51AM	Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Sep-30-25 02:49PM	Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) (Insider Monkey)
Sep-29-25 09:02AM	Nvidia Has Invested in These 6 Companies. Should You Follow Suit? (Motley Fool)
01:22AM	Jim Cramer on Recursion: "I Need to See a Proof of Concept Here" (Insider Monkey)
Sep-28-25 10:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
09:32AM	The Biotech Stock That's Too Risky for Most Investors (Motley Fool)
07:00AM	Nvidias $100 billion OpenAI investment raises eyebrows and a key question: How much of the AI boom is just Nvidias cash being recycled? (Fortune)
Sep-27-25 06:45AM	10 Hidden-Gem AI Stocks to Buy Right Now (Motley Fool)
Sep-26-25 04:42AM	Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now (Motley Fool)
09:15AM	Loading…
Sep-25-25 09:15AM	Looking for the Next Big Pop? Heres Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce (Barchart) -5.12%
Sep-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why (Zacks)
Sep-21-25 09:26AM	Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances (Insider Monkey)
Sep-15-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:17AM	Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 (Insider Monkey)
04:44AM	Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch. (Motley Fool)
Sep-03-25 06:00AM	When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts (Motley Fool)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:45AM	3 AI Stocks Disrupting Trillion-Dollar Industries (Motley Fool)
Aug-29-25 08:30AM	If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-28-25 05:05AM	Recursion Pharmaceuticals, Inc. (RXRX) Expands Rare Disease Pipeline with REV102 Acquisition (Insider Monkey)
Aug-27-25 08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
06:45AM	1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sell (Motley Fool)
Aug-24-25 12:53AM	Needham Maintains Buy Rating on Recursion (RXRX) (Insider Monkey)
04:00AM	Loading…
Aug-23-25 04:00AM	The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode (Motley Fool)
Aug-22-25 05:53PM	Why Recursion Pharmaceuticals Stock Caught a Cold This Week (Motley Fool)
Aug-21-25 10:45AM	Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-17-25 06:16PM	Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid (Insider Monkey)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.36%
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-10-25 05:20AM	3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term (Motley Fool)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:00AM	Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Aug-06-25 11:48AM	RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down (Zacks)
Aug-05-25 08:55PM	Recursion Sets $100 Million Partnership Goal by 202 (GuruFocus.com)
06:21PM	Why Recursion Pharmaceuticals Stock Tanked on Tuesday (Motley Fool)
07:45AM	Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
06:45AM	Recursion Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-25 12:23PM	Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? (Zacks)
Aug-03-25 12:32PM	2 Beaten-Down Stocks With Incredible Upside Potential (Motley Fool)
Jul-31-25 10:00AM	Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-30-25 05:45PM	Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Jul-29-25 05:50PM	Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today (Zacks) -5.71%
08:00AM	Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th (GlobeNewswire)
Jul-28-25 06:43PM	Why Recursion Pharmaceuticals Stock Got Mashed on Monday (Motley Fool)
Jul-26-25 06:14PM	The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. (Motley Fool)
Jul-25-25 11:33AM	RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? (Zacks)
Jul-23-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
10:07AM	3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities (Motley Fool)
10:02AM	Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? (Zacks)
Jul-22-25 03:42PM	Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings (Insider Monkey)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Jul-21-25 11:11AM	Why Is Recursion Pharma Stock Surging On Monday? (Benzinga) +9.59%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:11AM	Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock? (Zacks)
12:14AM	Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia (Insider Monkey)
Jul-17-25 05:50PM	Recursion Pharmaceuticals (RXRX) Rises Higher Than Market: Key Facts (Zacks) +5.80%
11:30AM	Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock (Zacks)
Jul-16-25 09:58AM	Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? (Zacks)
Jul-12-25 04:30AM	Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch. (Motley Fool)
Jul-10-25 05:50PM	Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing (Zacks) -7.61%
12:39AM	Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating (Insider Monkey)
Jul-09-25 02:22PM	Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia (Insider Monkey)
11:56AM	RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program (Zacks)
08:16AM	Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M (TipRanks)
Jul-08-25 02:30PM	Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking (Insider Monkey) +8.72%
01:28PM	Here's Why Shares in Recursion Pharmaceuticals Surged Today (Motley Fool)
08:00AM	Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia (GlobeNewswire)
08:00AM	Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals (Business Wire)
Jul-07-25 10:23AM	Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? (Zacks) -6.45%
09:30AM	Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for Investors (PR Newswire)
Jul-03-25 05:50PM	Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today (Zacks)
08:35AM	MS initiates coverage on AI Biotechs, flags key pipeline catalysts (Investing.com)
Jul-02-25 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
02:42AM	MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy (Insider Monkey)
Jun-28-25 12:00PM	Why This Wildcard Stock Could Be a Future Star (Barchart)
Jun-27-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -6.85%
Jun-20-25 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
Jun-16-25 05:30AM	Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? (Motley Fool)
Jun-11-25 05:57AM	Insmed surges on lung drug data; Recursion cuts staff (BioPharma Dive)
Jun-10-25 04:35PM	Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday (Motley Fool)
Jun-07-25 02:38PM	Why Recursion Pharmaceuticals (RXRX) Soared On Friday (Insider Monkey)
Jun-06-25 10:00AM	MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy (GlobeNewswire) +20.13%
Jun-05-25 11:31AM	Why Is Zoetis (ZTS) Up 8.1% Since Last Earnings Report? (Zacks) -6.92%
Jun-04-25 11:50PM	Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today (Insider Monkey) +11.85%
02:36PM	AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names (PR Newswire)
11:30AM	Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
May-30-25 08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.07%
May-27-25 10:00AM	RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? (Zacks) +7.60%
May-26-25 08:05PM	3 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
May-22-25 11:57AM	These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio (MarketBeat)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibson Christopher	Chief Executive Officer	Oct 10 '25	Sale	6.04	100,000	604,000	974,229	Oct 10 06:03 PM
Gibson Christopher	Officer	Oct 10 '25	Proposed Sale	6.04	100,000	604,000		Oct 10 10:24 AM
Gibson Christopher	Chief Executive Officer	Sep 25 '25	Sale	4.76	100,000	476,000	954,229	Sep 26 06:32 PM
Gibson Christopher	Officer	Sep 25 '25	Proposed Sale	4.76	100,000	476,000		Sep 25 09:49 AM
Gibson Christopher	Chief Executive Officer	Sep 10 '25	Sale	4.71	100,000	471,000	974,229	Sep 12 04:24 PM
Gibson Christopher	Officer	Sep 10 '25	Proposed Sale	4.71	100,000	471,000		Sep 10 11:10 AM
Gibson Christopher	Chief Executive Officer	Aug 26 '25	Sale	4.84	100,000	484,000	954,229	Aug 28 08:00 PM
Gibson Christopher	Officer	Aug 26 '25	Proposed Sale	4.84	100,000	484,000		Aug 26 10:03 AM
Khan Najat	Chief R&D Commercial Officer	Aug 18 '25	Sale	5.52	36,599	202,173	668,197	Aug 19 06:22 PM
Khan Najat	Officer	Aug 18 '25	Proposed Sale	5.52	36,599	202,169		Aug 18 03:18 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	500,300	2,641,584	1,004,619	Aug 13 09:03 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	117,875	622,380	0	Aug 13 09:03 PM
Gibson Christopher	Officer	Aug 11 '25	Proposed Sale	5.28	617,875	3,262,380		Aug 11 03:31 PM
Gibson Christopher	Chief Executive Officer	Mar 27 '25	Sale	6.04	138,574	836,987	1,117,450	Mar 28 04:52 PM
Gibson Christopher	Officer	Mar 27 '25	Proposed Sale	6.04	138,574	836,987		Mar 27 12:02 PM
Gibson Christopher	Chief Executive Officer	Mar 05 '25	Sale	6.58	20,000	131,600	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '25	Sale	6.37	20,000	127,400	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Officer	Mar 06 '25	Proposed Sale	6.37	20,000	127,400		Mar 06 11:55 AM
Gibson Christopher	Officer	Mar 05 '25	Proposed Sale	6.58	20,000	131,600		Mar 05 10:13 AM
Gibson Christopher	Chief Executive Officer	Feb 06 '25	Sale	8.12	20,000	162,400	1,273,156	Feb 07 04:14 PM
Gibson Christopher	Chief Executive Officer	Feb 05 '25	Sale	7.68	20,000	153,600	1,273,156	Feb 07 04:14 PM
Gibson Christopher	Officer	Feb 06 '25	Proposed Sale	8.12	20,000	162,400		Feb 06 10:40 AM
Gibson Christopher	Officer	Feb 05 '25	Proposed Sale	7.68	20,000	153,600		Feb 05 09:44 AM
Marriott Tina	Officer	Jan 30 '25	Proposed Sale	7.49	6,000	44,947		Jan 30 04:13 PM
Secora Michael	Former Officer	Jan 17 '25	Proposed Sale	6.51	5,000	32,573		Jan 17 05:09 PM
Secora Michael	Former Officer	Jan 15 '25	Proposed Sale	6.57	15,000	98,519		Jan 15 04:12 PM
Secora Michael	Former Officer	Jan 14 '25	Proposed Sale	6.48	15,000	97,246		Jan 14 04:21 PM
Gibson Christopher	Chief Executive Officer	Jan 08 '25	Sale	7.31	20,000	146,200	736,633	Jan 13 05:26 PM
Gibson Christopher	Chief Executive Officer	Jan 10 '25	Sale	7.05	20,000	141,000	736,633	Jan 13 05:26 PM
Gibson Christopher	Officer	Jan 10 '25	Proposed Sale	7.05	20,000	141,000		Jan 10 10:58 AM
Gibson Christopher	Officer	Jan 08 '25	Proposed Sale	7.31	20,000	146,200		Jan 08 10:30 AM
Marriott Tina	Officer	Dec 26 '24	Proposed Sale	7.46	6,000	44,761		Dec 26 04:24 PM
Secora Michael	Officer	Dec 11 '24	Proposed Sale	7.48	15,000	112,182		Dec 11 04:48 PM
Secora Michael	Officer	Dec 10 '24	Proposed Sale	7.75	15,000	116,324		Dec 10 04:56 PM
Gibson Christopher	Chief Executive Officer	Dec 04 '24	Sale	7.16	20,000	143,200	736,633	Dec 06 05:46 PM
Gibson Christopher	Chief Executive Officer	Dec 05 '24	Sale	7.12	20,000	142,400	736,633	Dec 06 05:46 PM
Gibson Christopher	Officer	Dec 05 '24	Proposed Sale	7.12	20,000	142,400		Dec 05 10:29 AM
Gibson Christopher	Officer	Dec 04 '24	Proposed Sale	7.16	20,000	143,200		Dec 04 10:32 AM
Marriott Tina	Officer	Nov 21 '24	Proposed Sale	5.78	6,000	34,702		Nov 21 04:24 PM
Gibson Christopher	Chief Executive Officer	Nov 13 '24	Sale	7.74	20,000	154,800	762,656	Nov 15 06:52 PM
Gibson Christopher	Chief Executive Officer	Nov 14 '24	Sale	7.35	20,000	147,000	762,656	Nov 15 06:52 PM
Borgeson Blake	Director	Nov 12 '24	Sale	7.64	11,447	87,457	7,066,113	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 13 '24	Option Exercise	2.22	39,375	87,413	1,514,631	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 12 '24	Option Exercise	2.22	39,375	87,413	1,490,256	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 13 '24	Sale	7.66	15,000	114,876	1,499,631	Nov 14 07:19 PM
Secora Michael	Chief Financial Officer	Nov 12 '24	Sale	7.64	15,000	114,628	1,475,256	Nov 14 07:19 PM
Gibson Christopher	Officer	Nov 14 '24	Proposed Sale	7.35	20,000	147,000		Nov 14 01:06 PM
Secora Michael	Officer	Nov 13 '24	Proposed Sale	7.66	15,000	114,876		Nov 13 04:34 PM
Gibson Christopher	Officer	Nov 13 '24	Proposed Sale	7.74	20,000	154,800		Nov 13 10:11 AM
Borgeson Blake	Director	Nov 12 '24	Proposed Sale	7.64	11,447	87,458		Nov 12 04:40 PM
Secora Michael	Officer	Nov 12 '24	Proposed Sale	7.52	15,000	112,800		Nov 12 02:48 PM
Borgeson Blake	Director	Oct 29 '24	Sale	6.72	11,447	76,926	7,077,560	Oct 31 06:01 PM
Borgeson Blake	Director	Oct 29 '24	Proposed Sale	6.72	11,447	76,926		Oct 29 04:35 PM
Marriott Tina	President and COO	Oct 24 '24	Option Exercise	1.06	6,000	6,360	527,138	Oct 28 05:25 PM
Marriott Tina	President and COO	Oct 24 '24	Sale	6.31	6,000	37,855	521,138	Oct 28 05:25 PM
Marriott Tina	Officer	Oct 24 '24	Proposed Sale	6.31	6,000	37,855		Oct 24 04:22 PM
Burrell Terry-Ann	Former BOD	Oct 17 '24	Proposed Sale	6.66	404,688	2,693,813		Oct 17 05:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience